methotrexate + sarilumab

Methotrexate + sarilumab is a combination therapy used primarily for the treatment of moderate to severe rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). Methotrexate is a conventional synthetic DMARD that inhibits dihydrofolate reductase, interfering with DNA synthesis and immune cell proliferation. Sarilumab is a human monoclonal antibody that targets the interleukin-6 receptor (IL-6R), blocking IL-6-mediated inflammatory signaling. The combination leverages methotrexate’s broad immunosuppressive effects and sarilumab’s targeted inhibition of IL-6 signaling, resulting in improved control of inflammation and joint damage compared to monotherapy. This regimen is typically prescribed when patients do not respond adequately to methotrexate alone[2][3][5][8].

Brand names

Kevzara

Other names

sarilumab + MTX